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A B S T R A C T
Introduction: Several questions about pregnancy in women with multiple sclerosis (MS) have been discussed, but
clarification is still needed in some very practical issues. Portuguese data on this subject remain scattered and
need to be analyzed in order to standardize clinical practice.
Objective: This study aimed to describe and analyze the impact of MS on pregnancy and perinatal health of
children born to Portuguese mothers with the disease.
Material and methods: This is a multicenter, retrospective study of a cohort of Portuguese women with MS who
were pregnant and who gave birth between 01/01/2011 and 31/12/2015. Demographic and clinical data re-
lated to maternal disease, pregnancy progression and events, childbirth and newborn health were collected.
Results: Ninety-seven women were recruited and 90 live births were evaluated. The mean maternal age at
conception was 32.5 years, and 63.9% had no relapses in the previous year (98.0% had a relapsing-remitting MS
and the EDSS score was≤3 in 92.8% of the cases). Only 50.5% of the women had a preconception specific
evaluation and 60 children were exposed to immunomodulatory therapies during pregnancy. Nineteen women
had relapses during pregnancy. Childbirth was induced in 22.7% of the cases, and the caesarean section rate was
34%. Children exposed to immunomodulatory drugs during pregnancy had a lower birth length (p=0.014), and
there was also a trend toward lower birth weight (p=0.054) in these newborns. Pre-conception EDSS score
negatively correlated with the duration of pregnancy (r= -0.22; p=0.029), weight (r=-0.23; p=0.031) and
cephalic perimeter at birth (r= -0.24; p=0.033). There was no relationship between the occurrence of relapses
or progression in EDSS score during pregnancy with any variables related to the newborn.
Conclusions: In our cohort, it has been confirmed that MS has no negative effect on pregnancy or on children's
perinatal health. However, the use of immunomodulatory drugs may have some impact on newborns’ somato-
metric features.
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1. Introduction
Multiple sclerosis (MS) usually affects women in childbearing age,
making the effect of pregnancy on the disease (and vice versa) an im-
portant clinical issue (Voskuhl and Momtazee, 2017). It is now well
established that the risk of relapse significantly declines during preg-
nancy, particularly during the third trimester, only to increase three-
fold in the first three-to-four months postpartum, compared with the
pre-pregnancy period (Nelson et al., 1988; Confavreux et al., 1998).
This 70% reduction in disease activity during the third trimester was
firstly reported in the PRIMS (Pregnancy in Multiple Sclerosis) study, a
relatively large-scale multicenter prospective study (Confavreux et al.,
1998). Nevertheless, inconsistent results have been observed regarding
the effect of MS on pregnancy outcomes and on the prognosis for long-
term disability. While the majority of studies claims that MS does not
increase adverse pregnancy outcomes (Poser and Poser, 1983;
Sadovnick et al., 1994; Mueller et al., 2002; Van der Kop et al., 2011;
Finkelsztejn et al., 2011), some studies reported that mothers with MS
are more likely to have infants with low birth weight for the gestational
age (Kelly et al., 2009; Chen et al., 2009; Dahl et al., 2005, 2008;
Hellwig et al., 2008), or prematurely born (Chen et al., 2009), com-
pared to healthy women. Other studies reported a greater likelihood of
assisted vaginal delivery (Jalkanen et al., 2010) and cesarean delivery
(Kelly et al., 2009) for those women diagnosed with MS. Regarding
long-term disability, no studies have found a harmful effect of preg-
nancy. While some studies found no association (Ramagopalan et al.,
2012; Thompson et al., 1986; Weinshenker et al., 1989), others sug-
gested a protective effect (Jokubaitis et al., 2016; Runmarker and
Andersen, 1995; D'Hooghe et al., 2012, 2010) on this disorder. More-
over, the role of breastfeeding as a modifiable risk factor of postpartum
relapses remains unclear: previous studies found either no association
(Nelson et al., 1988; Confavreux et al., 1998; Portaccio et al., 2011) or a
protective effect, particularly of exclusive breastfeeding (Langer-Gould
et al., 2009; Gulick, 2002).
Over the last few years, some studies addressed the effect of disease-
modifying treatments (DMTs) for MS on pregnancy and birth outcomes
and on disease course. There is some evidence that pregnant women
exposed to DMTs during pregnancy or in the 2 years preceding con-
ception are less likely to have postpartum relapses (Fragoso et al., 2013;
Hughes et al., 2014) and EDSS progression (Fragoso et al., 2013) than
women who were not exposed to any DMT. Most treating physicians
tend to advice the resumption of DMT after delivery, although the
optimal time to restart the DMT and other appropriate measures to
prevent postpartum relapses remain unclear (Alroughani et al., 2018).
A recent Portuguese unicentric study also concluded that MS did not
have a deleterious effect on pregnancy outcome (Jesus-Ribeiro et al.,
2017). However, there is still a need for collecting multicentric data as
an initial effort to create a Portuguese MS Pregnancy Registry. This
multicentric study aims to describe and analyze the effect of MS on
pregnancy and perinatal health of children born to mothers with this
disease in Portugal.
2. Methods
“Pregnancy outcomes in Portuguese women with multiple sclerosis”
(PREGNIMS) is an investigator-initiated, multicenter, retrospective co-
hort study conducted to describe the effects of MS on pregnancy and
fetal outcomes in Portuguese women with MS. Recruitment was con-
secutively performed, including female patients with a previous diag-
nosis of MS fulfilling 2010 McDonald Criteria (Polman et al., 2011),
who had at least one delivery between 1st January 2011 and 31st De-
cember 2015, and that were under follow-up in specialized MS clinics in
nine Portuguese hospitals. Women with other neurological conditions,
deemed to impact pregnancy outcomes, were excluded. We collected
data concerning maternal clinical characteristics, pregnancy course and
outcome, delivery and newborn clinical status. We extended data
collection during the 1-year postpartum period to include information
related to the resumption of immunomodulatory therapy (and the
variables that conditioned it), the relapses, and the progression of dis-
ability during that period of time. Data were collected from medical
records, individual pregnancy records, infantile individual health re-
cords and when necessary, through individual interviews with the pa-
tients. The National Data Protection Commission and the local Ethics
Committees from the involved centers approved this study. Patients
gave written informed consent to participate in the study.
Considering the statistical analysis, continuous variables were tested
for normality using the Kolmogorov-Smirnov goodness of fit test.
Baseline features are presented as frequency (percentage) for dichot-
omous variables, median± interquartile range (IQR) for quantitative
variables without normal distribution and mean± standard deviation
(SD) for normally distributed quantitative variables. Comparisons be-
tween two groups were made using independent-samples T-test for
normally distributed variables, Mann–Whitney U test for quantitative
variables not normally distributed and Chi-square (χ2) test for cate-
gorical variables. For matched samples the Wilcoxon test was used.
Pearson's correlation (or Spearman correlation if normality was not
assumed) was used to assess the correlation between quantitative
clinical variables. To compare the subgroups of DMTs in relation to the
somatometric characteristics of newborns ANOVA test and Bonferroni
correction were applied. The level of statistical significance was set at
p<0.05 for all analyses. IBM SPSS Statistics® (version 25) was used for
statistical analysis.
3. Results
3.1. MS and pregnancies
We identified a total of 107 pregnancies in the study period. In cases
corresponding to several pregnancies of the same woman, only the first
gestation was included. Thus, 97 pregnancies resulting in 90 live births
were eligible for analysis.
The baseline characteristics of maternal MS are resumed in Table 1.
The mean maternal age at conception was 32.5 (± 4.3) years (range
17–41). The majority of women (n=62; 63.9%) had no relapses in the
year prior to conception, 28 had 1 relapse (28.9%), 6 had 2 relapses
(6.2%) and 1 had 3 relapses (1.0%) in the same time period. Also the
majority had an Expanded Disability Status Scale (EDSS) score≤ 3.
Only 32 (33.0%) women had a planned pregnancy and previously
discontinued the DMT, although 49 (50.5%) reported a prior con-
sultation on family planning. In 25 cases (25.8%), patients and/or their
neurologists opted to use DMT during pregnancy, especially at very
early stages, until the pregnancy was effectively diagnosed.
At the time of pregnancy diagnosis (mean 5.9 ± 3.5 weeks), 57
woman (89.1%) suspended DMT. In total, 65 were exposed to DMT,
mostly during the first trimester and until the pregnancy was diag-
nosed. The mean total exposure time was 8.0 ± 9.2 (range 1–41)
Table 1
Baseline characteristics of mothers’ MS
Baseline characteristics n=97
Age at MS diagnosis, mean±SD (min-max), years 25.6± 5.6 (9-36)
MS course
Relapsing-remitting MS, n (%) 95 (98.0)
Primary progressive MS, n (%) 1 (1.0)
Secondary progressive MS, n (%) 1 (1.0)
Annualized relapse rate prior to conception, mean± SD 0.4± 0.7
Duration of MS at conception, mean± SD (max-min), years 6.9± 5.2 (1-26)
EDSS at conceptiona, median± IQR (min-max) 1.0± 2.0 (0-6)
EDSS ≤ 3, n (%) 90 (92.8)
EDSS > 3, n (%) 7 (7.2)
a Measured at the last visit before pregnancy diagnosis or at the first ap-
pointment after becoming pregnant
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weeks. Fifty-nine (90.8%) patients were exposed to first-line DMT
(mean exposure time 7.8 ± 9.4 weeks) and 3 (4.6%) were exposed to
second-line DMT, namely to natalizumab (mean exposure time
10.7 ± 6.1 weeks).
Clinical data of pregnancies are shown in Table 2, divided according
to DMT exposure status. Four women intentionally maintained DMT
(glatiramer acetate, GA) throughout pregnancy due to severe disease in
the past and fear of disease reactivation during pregnancy or im-
mediately after delivery.
Five women restarted treatment between 16 and 3 weeks before
delivery, due to the occurrence of relapses (natalizumab was pre-
scribed) or active disease prior to conception despite the absence of
relapses throughout pregnancy [GA or intravenous immunoglobulin
(IVIg)]. Table 3 depicts other immunomodulators used during preg-
nancy.
The relapse rate during pregnancy had a mean of 0.3, without clear
predominance in a specific trimester. There is very weak positive cor-
relation (r=0.224; p=0.027) between the relapse rate during preg-
nancy and EDSS score prior to pregnancy. Other indicators of disease
severity, such as the occurrence of relapses in the 12 months prior to
gestation or the duration of the disease did not influence relapse rate
during pregnancy. There was also no statistically significant difference
in the relapse rate between those exposed and not exposed to DMT
during pregnancy, regardless of the exposure time and the DMT class
(1st or 2nd line therapies).
Labor induction was necessary in 20 (22.7%) cases, and epidural
anesthesia was used in 71 (78.9%) women. The different types of de-
livery were registered as follows: vaginal delivery (n=38; 39.2%),
emergent caesarean (n=16; 16.5%), elective caesarean (n=17;
17.5%), vacuum extraction (n=11; 11.4%) and forceps delivery
(n=7; 7.2%); data were missing in 8 cases (8.2%). The main reasons
for caesarean section were fetal distress (n=15) and maternal disease
(n=9). The need for labor induction was associated with older age at
pregnancy onset (t(37.7)=−2,23; p=0.031) and was not associated
with disease clinical phenotype.
Women with relapses during pregnancy did not have higher fre-
quency of caesarean delivery (p=0.322). Conversely, the need for
assisted delivery (forceps and vacuum extraction) was associated with
relapses in pregnancy (χ2(1)= 12.4; p=0.001), as well as increased
EDSS score between pre- and postpartum (t(20.24)=−2.64,
p=0.016), but was not related to corticosteroid (CT) use during
pregnancy (p=0.416) or to somatometric characteristics of the new-
born (cephalic perimeter: t(79)= 0.96, p=0.340; birth length: t
(84)=−1.37, p=0.172; birth weight: t(58.6)=−1.03, p=0.307).
In the first year after childbirth, 92.2% of women restarted DMT,
but only 13.3% restarted treatment in the immediate postpartum period
(during the first seven days after delivery), in accordance with their
physicians’ recommendation. Eighty percent chose to breastfeed and,
hence, the mean delay time until DMT restart was 3.0 months. Twenty-
eight women (30.8%) had at least one relapse in the first year after
delivery and the mean time until this happened was 4.0 months (range
2–12). Using survival analysis, it was possible to see that the use of
DMT, the type of DMT [GA, interferon beta (IFN), or second-line DMT],
corticosteroids or IVIg use in pregnancy, as well as the relapse rate
during pregnancy and in the prior year, did not have any impact in time
until the first postpartum relapse.
The EDSS score after delivery was assessed at the first consultation
with the assistant neurologist, sometimes several months after delivery,
not controlling the possibility of a new relapse occurring in that in-
terval. The median postpartum EDSS was 1.0, corresponding to a sta-
tistical significant increase in pre- and post-pregnancy EDSS score by
27.8% (r=0.850; p<0.001).
3.2. MS and newborns
The characteristics of the population of newborns are summarized
in Table 4. There were no perinatal deaths and there were minor
malformations in 3 babies (3.3%): pilonidal sinus, bilateral ectasia of
kidney pelvis and congenital torticollis (none of these situations re-
quired additional hospitalization). Pregnancy duration was not sig-
nificantly influenced by the occurrence of relapses or by the exposure to
MS treatments. On the other hand, pre-conception EDSS score nega-
tively correlated with the duration of pregnancy (r=−0.22;
p=0.029), weight (r=−0.23; p=0.031) and cephalic perimeter at
birth (r=−0.24; p=0.033). The occurrence of relapses or an increase
Table 2
Baseline characteristics of pregnancies and comparative analysis with exposure to DMT
Baseline characteristics With DMTa (n=65) Without DMT (n=32) p-value
Result of pregnancy ˃ 0,05
Live births, n (%) 60 (92.3) 30 (93.8)
Spontaneous abortion, n (mean± SD weeks) 4 (9.3±4.7) 1 (8)
Pregnancy termination, n (mean, week)
Voluntary 1 (8) 0
Due to major fetal malformation 0 1 (11)
Pregnancy duration, mean±SD (min-max), weeks 36.2± 8.2 (5-42) 36.9±7.3 (8-41) ˃ 0,05
Relapses during pregnancy, n (%) 14 (21.5) 5 (15.6) ˃ 0,05
1 relapse, n (1T, 2T, 3T)b 8 (2,4,2) 5 (2,3,0)
2 relapses, n (1T, 2T, 3T)b 3 (1,4,1) 0 (0,0,0)
≥ 3 relapses, n (1T, 2T, 3T)b 3 (2,3,6) 0 (0,0,0)
Other gestational complications, n (%) 14 (21.5) 3 (9.4)
Gestational diabetes 6 0 ˃ 0,05
Eclampsia 0 0
Preeclampsia 5 1 ˃ 0,05
Otherc 3 2
a Exposure ranging from 1 to 41 weeks;
b 1T – first trimester; 2T – second trimester; 3T – third trimester;
c placental abruption, repeated urinary tract infections, arterial hypertension
Table 3
Other treatments during pregnancy
Treatment characteristics
Corticosteroid, n (%) 12 (12.4)
Total days, mean± SD (min-max) 7.7±4.9 (3-20)
Total dose, mean±SD (min-max), g 7.5±5.0 (1.5-20)
IVIg, n (%) 4 (4.1)
Total days, mean± SD (min-max) 5.8±2.9 (2-8)
Total dose, median (min-max), g 117.5 (48-1280)
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of EDSS score during pregnancy had no impact on neonate weight,
length and cephalic perimeter at birth.
DMT exposure at any time during pregnancy had a statistical sig-
nificant impact on birth length (t (85 )= 2.13; p=0.014), but not in
other variables. Nevertheless, a trend toward a statistically significant
difference was observed in birth weight, with those exposed to DMT
tending to weight less than those not exposed (p=0.054). In the sub-
group analysis of DMTs there were no significant differences on new-
born somatometric characteristics when comparing those exposed to
first-line DMTs (GA vs IFN), GA and any other DMTs (including second-
line drugs), or those exposed to GA vs no DMTs.
Children born to mothers who received DMT during pregnancy had
longer hospitalizations after birth, comparing to children not exposed
to DMT (t(88)= 2.00; p=0.048), but no significant medical inter-
currences were documented.
4. Discussion
This study represents a first look into the overall reality of preg-
nancy outcomes in Portuguese MS patients. We were able to collect data
from centers from every region of the continental territory (north,
center, south) as well as from almost all major neurological centers
treating MS patients, allowing a comprehensive survey of disease
management practices among Portuguese neurologists and ob-
stetricians dealing with this particular patient group.
Overall, the outcome of the patients and their offspring was good
and comparable to data from other MS populations. Five percent of the
pregnancies ended in miscarriage, which is in line with the findings of
the PRIMS study (Confavreux et al., 1998). Other main complications
included gestational diabetes (6%) and preeclampsia (6%), which were
within the observed in other cohorts that report between 3.9% and
14.8% incidence of gestational diabetes (Van der Kop et al., 2011;
Jalkanen et al., 2010) and between 4.9% and 10.7% of hypertension-
related complications. (Kelly et al., 2009; Jalkanen et al., 2010) There
were no perinatal deaths and malformations were minor in only 3 ba-
bies (3.3%).
Differently to what is described in the literature (Nelson et al., 1988;
Confavreux et al., 1998; Hellwig et al., 2012), there was a small but not
statistically-significant relapse rate reduction between the pre-concep-
tion and gestational period. This is probably due to an already low pre-
conception relapse rate in our cohort when compared to other series,
which report pre-conception annualized relapse rates between 0.68–1.2
(Confavreux et al., 1998; Jalkanen et al., 2010; Hellwig et al., 2012;
Fragoso et al., 2013). This could be explained by better treatment re-
sponses and/or to the fact that only women with more benign or better-
controlled disease decided to proceed with pregnancy in our specific
cultural setting. The use of, type or time of exposure to DMT during
pregnancy did not seem to influence the rate of relapses during preg-
nancy either. Another study addressing this issue found that both pa-
tients with or without DMT use during pregnancy experienced a re-
duction of relapse rate throughout gestational period and that DMT use
did not confer special protection (Hellwig et al., 2012).
In our cohort, we observed a significant increase in the EDSS score
between the pre-pregnancy year and the post-partum period. Our
finding is not in line with previous evidence showing no apparent ac-
celeration of the progression of disability in the post-partum period
compared to the earlier periods, despite the increase in the relapse rate
(Confavreux et al., 1998; Ramagopalan et al., 2012; Thompson et al.,
1986; Weinshenker et al., 1989). However, since we do not have data
on previous evolution of each patient, it is not possible to exclude that
the EDSS score might represent the natural evolution of the disease.
Moreover, we cannot exclude the existence of a certain overvaluation of
symptoms during the gestational period, in which there is a natural
hyper-vigilance of the woman herself.
When considering the effects of MS in child's outcome, we found a
weak correlation between higher pre-conception EDSS and shorter
pregnancy duration, lower birth weight and lower head circumference.
This probably reflects the impact of a more severe maternal MS on the
pregnancy. Literature results are mixed, with some studies finding si-
milar results (Kelly et al., 2009; Chen et al., 2009; Dahl et al., 2005,
2008; Hellwig et al., 2008) and others reporting no adverse outcomes
associated with MS (Poser and Poser, 1983; Sadovnick et al., 1994;
Mueller et al., 2002; Van der Kop et al., 2011; Finkelsztejn et al., 2011).
The use of DMT, particularly interferon beta during pregnancy has also
been associated with lower weight and length and lower gestational age
at birth. (Lu et al., 2012) In our cohort, pregnancies exposed to DMT led
to neonates with lower birth weight and length and this included all the
preterm births; however only newborn's length was significantly dif-
ferent between the exposed and non-exposed pregnancies. There was
also no significant association when testing for different DMTs. As such,
our results point toward a relative safety of these drugs on newborn
outcomes, while disease severity might have more impact on these
measures.
A few studies have found that DMT use during pregnancy (mostly
only during the first trimester) had a significant effect in reducing the
relapse rate and disability progression postpartum. (Hellwig et al.,
2012; Fragoso et al., 2013) In our cohort, we found that neither use nor
duration of exposure to DMT during pregnancy appeared to have a
significant impact on the time until the first postpartum relapse. We did
find an increased risk of postpartum relapse in patients using two DMTs
during pregnancy, most likely reflecting a more severe and active dis-
ease, requiring more intensive treatment. Since randomized trials with
DMTs in pregnant women are not feasible, data from observational and
open studies are a crucial source of information on this issue. Our study
points toward a small risk associated with DMT use in pregnancy, albeit
with no measurable benefit.
There is no consensus approach on DMT usage in a prospective
mother with MS. A recent survey of European MS neurologists showed a
near 50/50 divide between those who favored discontinuation of DMT
previous to conception in stable relapsing-remitting MS patients and
those who did not (Fernández et al., 2018). In our cohort, we found
that, in around one third of cases, women and/or physicians opted to
maintain DMT while attempting to conceive.
In our study, a caesarean section was performed in 34% of de-
liveries, which is quite comparable to data from the Portuguese general
population from the same time frame of this study (2009–2015), which
Table 4
Characteristics of newborns
Baseline characteristics Total With DMTa Without DMT P-value
Weight at birth, mean± SD, g 3053.3±466.7 2991.0± 457.3 3177.7± 357.2 0.054
Length at birth, mean± SD, cm 48.2± 2.8 47.7±3.1 49.1± 1.9 0.014
Cephalic perimeter at birth, mean± SD, cm 34.3± 1.7 34.1±1.9 34.7± 1.3 0.118
Prematurity, n (%) 5 (8.3) 5 (8.3) 0 (0.0) 0.266
32-36 weeks, n 4 4 0
28 weeks, n 1 1 0
Hospitalization after birth, mean± SD, days 3.7±1.8 3.9± 2.1 3.1± 0.9 0.048
a Exposure ranging from 1 to 41 weeks.
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was 33.1–36.6% (Ayres-De-Campos et al., 2015). While some studies
show MS is not associated with an increased rate of caesarean sections
(Van der Kop et al., 2011; Jalkanen et al., 2010), these were studies
made in populations with low rates of this procedure (from 10–18% of
deliveries). On the other hand, another study in a population with rates
of caesarean sections closer to ours found MS to be associated with an
increased risk of caesarean section.
A few studies have previously showed an increased rate of assisted
delivery in patients with MS, when compared with the general popu-
lation. (Dahl et al., 2005; Jalkanen et al., 2010) Results from our cohort
show that more relapses during pregnancy are associated with the need
for assisted delivery (forceps or vacuum extraction) and with an in-
crease in the EDSS score postpartum. Neuromuscular weakness and/or
sensitive deficits induced by relapses and fatigue due to higher disease
activity might explain this increased risk. We did not find an association
between assisted delivery and newborn somatometric variables, in op-
position to data from the general population. (Rabei et al., 2017)
There are some limitations to this study to be considered. Firstly, its
retrospective design and the possibility of recall bias in reporting data.
However, the consultation of the medical records and the individual
pregnancy and infantile health records reduced a possible negative ef-
fect of these circumstances in our results. Secondly, the patients pre-
sented relatively mild disability and most of them had a relapsing-re-
mitting subtype of MS. Therefore, we could not define if the results of
the current study are fully applicable to all MS patients. Finally, the lack
of a control group, precluding comparisons between pregnant women
with and without MS, is also a point worth mentioning.
5. Conclusion
Our study is the first multicenter report about the reality of preg-
nancy outcomes in Portuguese MS patients. Overall, our results de-
monstrate that MS does not appear to have a negative impact on the
main outcomes of pregnancy, but a more severe maternal disease pre-
viously and during the pregnancy (EDSS score) seems to have a nega-
tive impact on the length of newborns, also conditioning a trend to
lower body weight at birth. We also observed a small risk associated
with DMT use in pregnancy, albeit with no measurable benefit. Due to
great variability around the many features of pregnancy management in
MS patients, as well as the paucity of data about newborns’ outcomes,
there is a need to broaden the discussion of these aspects in order to
standardize clinical procedures.
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